Estimating the Allocation of the Economic Value Generated by Utilization of All-Oral Direct-Acting Antivirals for Hepatitis C in the United States, 2015 to 2019.
Louis P GarrisonBoshen JiaoZizi ElsisiAlon YehoshuaRoy KoruthBruce KreterJens GruegerPublished in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2024)
The significant majority (∼90%) of the economic value of curing HCV with DAAs were health benefits to patients and net cost-savings to society. DAA manufacturers received a minority share (6.5%) of the aggregate economic value generated.